Lifeboat Foundation

Let’s say it was possible to buy your health by the day. How much would you be willing to pay for each year of perfect health? What if you could buy years of health for your loved ones, too? At what price point would you draw the line?

This sort of difficult calculus, on a much larger and chronologically longer scale, underpins many decisions we make in medicine — not just decisions that we make as patients, but also the decisions that are made for us by employers, health insurance funders and policymakers. We don’t have the resources to pursue every possible treatment, to research every possible breakthrough, so how do we allocate the resources available? It turns out that there is an entire field of healthcare economics devoted to understanding the costs and benefits of conventional medicine, and to navigating the trade-offs between more expense and better healthcare.

Continue reading “Econogenomics: The Economics of Genomic Testing for Health” »

The National Institutes of Health is testing the antiviral drug remdesivir, which is also being studied in patients in China. Running trials during epidemics is tricky, but scientists learned a lot about how to conduct them during recent Ebola outbreaks.

But using porous TCP to print bones does have some drawbacks. Its compressive strength is much lower than that of some human load-bearing bones, such as our thighbones. Compressive strength would rise over time, but it could be years before it would match pre-operation strength levels.

3D Printing Bones for Mars?

Several other groups are working on similar approaches. At NYU School of Medicine and NYU Langone Health, scientists have been developing 3D printed scaffold implants that could help patient groups such as children with skull deform ities. Early research results show that up to 77 percent of the bone scaffolding had been absorbed and replaced by natural bone 6 months after surgery, and that the newly-grown bone was just as strong as the original.

Avigan was developed as a flu medicine and also has been used for Ebola virus disease (EVD) treatment. EVD, which causes fatal hemorrhagic fever, resulted in more than 11,300 deaths in the West Africa region between 2014 and 2016. There is currently another outbreak in the Democratic Republic of Congo that has seen more than 2,000 fatalities to date.

HONG KONG – Fujifilm Holdings Corp. stock (TYO:4901) jumped 8.8% to ¥5,890 (US$53.48) on Feb. 25, as Japan considers using Avigan (favipiravir), an anti-influenza medication developed by the company’s Toyama Chemical Co. Ltd., to treat COVID-19. The share price ended the day at ¥5,567, for a gain of 2.83%.

The medication attracted market attention when Minister of Health, Labor and Welfare Katsunobu Kato said on Feb. 22 that the country is planning to test Avigan against COVID-19. “We hear from foreign countries that some drugs among those that have been used against influenza may be useful,” Kato said.

Continue reading “Fujifilm stock rises as Japan considers Avigan for COVID-19 treatment” »

Would you want to know if you’re at risk of Alzheimer’s disease, for example?

The integration of sequencing into health care doesn’t fit very well in the model of how medicine is practiced today, but is well aligned with the future vision of health care that so many of us have — a vision that focuses upon prediction and prevention.

Continue reading “Genome Sequencing for Healthy People: Is it Time?” »

China has said that some vaccines for the novel coronavirus could be in clinical use next month as the number of global coronavirus cases soared past 100,000.

The country’s scientists are striving to develop immunisation products with five technologies simultaneously, according to officials.

Continue reading “The first coronavirus vaccine could be in ‘clinical use’ in April” »

My editorial from today’s (3/18/19) Financial Times:

Far sooner than most people realise, the genetics revolution will transform the world within and around us. Although we think about genetic technologies primarily in the context of healthcare, these tools are set to change the way we make babies, the nature of the babies we make and, ultimately, our evolutionary trajectory as a species — and we are not remotely ready for what’s coming. Yet we must be, to optimise the benefits and minimise the potential harms of genetic technologies.

Continue reading “Human gene editing is too transformative to be guided by the few” »

In a study of epilepsy patients, researchers at the National Institutes of Health monitored the electrical activity of thousands of individual brain cells, called neurons, as patients took memory tests. They found that the firing patterns of the cells that occurred when patients learned a word pair were replayed fractions of a second before they successfully remembered the pair. The study was part of an NIH Clinical Center trial for patients with drug-resistant epilepsy whose seizures cannot be controlled with drugs.

“Memory plays a crucial role in our lives. Just as musical notes are recorded as grooves on a record, it appears that our brains store memories in neural firing patterns that can be replayed over and over again,” said Kareem Zaghloul, M.D., Ph.D., a neurosurgeon-researcher at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and senior author of the study published in Science.

Dr. Zaghloul’s team has been recording electrical currents of drug-resistant epilepsy patients temporarily living with surgically implanted electrodes designed to monitor brain activity in the hopes of identifying the source of a patient’s seizures. This period also provides an opportunity to study neural activity during memory. In this study, his team examined the activity used to store memories of our past experiences, which scientists call episodic memories.

Powerful antibiotics and widespread sanitation practices have expanded lifespans across the industrialized world. But they have also come at a cost. Our microbiomes, or the trillions of microbes collectively working in our bodies to help regulate our immune system and food digestion, have lost much of its health-promoting bacteria because of our modern lifestyles and sanitation practices.

Scientists across the world are now looking to the planet’s few remaining pre-industrialized societies to see what industrialized guts have lost–and in doing so, could fundamentally change the way scientists think about germs. Thomas Morton heads to the Central African Republic to see this emerging field of microbiome science.

Continue reading “The Hunt for a Better Gut Bacteria in Central Africa” »